Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adsorbed diphtheria, tetanus and acellular pertussis (three-component) combined vaccine
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Adsorbed diphtheria, tetanus and acellular pertussis (three-component) combined vaccine (DTcP), marketed under the trade name Tripecia®, is a next-generation component-based vaccine developed by CanSino Biologics. Unlike traditional co-purified acellular pertussis vaccines, Tripecia® is formulated with three individually purified and genetically engineered pertussis antigens—pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN)—mixed in precise ratios with separately prepared diphtheria and tetanus toxoids. This component purification technology ensures high batch-to-batch consistency, stability, and a robust immune response while minimizing reactogenicity (such as fever). Tripecia® was approved by China's National Medical Products Administration (NMPA) in April 2026 for the active immunization of infants under 2 years of age against diphtheria, tetanus, and pertussis.
- Brand names
- Tripecia
- Other names
- adsorbed diphtheria, tetanus and acellular pertussis (three-component) combined vaccineadsorbed DTcP vaccineDTcP Infantdiphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed
02
Targets
FHA (Filamentous hemagglutinin)Diphtheria toxinPRN (Pertactin)
Beyond the preview
Go deeper on adsorbed diphtheria, tetanus and acellular pertussis (three-component) combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adsorbed diphtheria, tetanus and acellular pertussis (three-component) combined vaccine.